Strategic clients Certara serves about 2,000 biopharma companies, academic institutions, and regulatory agencies across 62 countries, indicating a broad potential for expanding enterprise software and services across existing and new customers with a focus on biosimulation and regulatory science.

AI and biosimulation focus Recent market commentary highlights differentiation between model-informed software offerings and data/record systems, suggesting opportunities to position Certara's biosimulation platform as the core AI-enabled engine for efficient drug discovery and development with targeted upsell to clients adopting AI strategies.

Financial appetite Significant investor interest from institutions like BlackRock and Bank of New York Mellon, alongside reaffirmed revenue outlook, implies strong market validation and potential to pursue larger cross-sell opportunities within existing client bases and growth-geared product bundles.

Expansion through services Q2 2026 indicators show software growth offsetting services decline, signaling a strategic cue to emphasize scalable software subscriptions, platform enhancements, and higher-margin offerings to stabilize revenue mix and drive renewals with enterprise clients.

Competitive positioning Certara operates in a competitive healthcare tech space with peers like IQVIA and Labcorp Drug Development; opportunities exist to differentiate through integrated biosimulation workflows, regulatory science expertise, and faster time-to-value for drug development programs.